基本信息
浏览量:280
职业迁徙
个人简介
I am a clinician-scientist with a strong interest in translating fundamental insights into clinical therapies, particularly in the field of cell therapy. Over the past 30 years, I have actively participated in numerous multicenter trials in which the University of Louisville has ranked in the top echelon of enrolling centers. For example, within the CCTRN the Louisville Center was the second top enrolling Center in PACE and is currently the top enrolling Center in CONCERT. I participated in RENEW and DREAM-HF (both studies of cell therapy). I am Chair of the DSMB for a new trial of bone marrow MSCs in patients with LVADs. I served on the Steering Committee of EXPEDITION, a multicenter international trial, and on the Protocol Review Committee of the first CCTRN (2007-12).
Over the past 30 years I have conducted numerous single-center, first-in-human studies pertaining to myocardial stunning, myocardial preconditioning, and stem cell therapies. For example, in the late 1990s and early 2000s I tested several preconditioning strategies (e.g., intracoronary adenosine, bradykinin, enalaprilat, physical exercise, etc.) in patients undergoing coronary angioplasty (Section C below). In 2009, after studying c-kit+ cardiac progenitor cells (CPCs) in preclinical models, I spearheaded the translation of this basic work to the clinic and obtained FDA approval for a Phase I trial of CPCs in patients with heart failure (SCIPIO) (Section C below). This was the first study of CPCs in humans. I designed, coordinated, and directed this study at Jewish Hospital in Louisville, and completed enrollment despite the stringent selection criteria.
Over the past 30 years I have conducted numerous single-center, first-in-human studies pertaining to myocardial stunning, myocardial preconditioning, and stem cell therapies. For example, in the late 1990s and early 2000s I tested several preconditioning strategies (e.g., intracoronary adenosine, bradykinin, enalaprilat, physical exercise, etc.) in patients undergoing coronary angioplasty (Section C below). In 2009, after studying c-kit+ cardiac progenitor cells (CPCs) in preclinical models, I spearheaded the translation of this basic work to the clinic and obtained FDA approval for a Phase I trial of CPCs in patients with heart failure (SCIPIO) (Section C below). This was the first study of CPCs in humans. I designed, coordinated, and directed this study at Jewish Hospital in Louisville, and completed enrollment despite the stringent selection criteria.
研究兴趣
论文共 1025 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Riham R. E. Abouleisa,Xian-Liang Tang,Qinghui Ou, Abou-Bakr M. Salama, Amie Woolard, Dana Hammouri, Hania Abdelhafez, Sarah Cayton, Sameeha K. Abdulwali, Momo Arai,Israel D. Sithu,Daniel J. Conklin,
CARDIOVASCULAR RESEARCHno. 2 (2024): 152-163
Texas Heart Institute journalno. 5 (2023)
Xian-Liang Tang, Marjan Nasr,Shirong Zheng,Taylor Zoubul,Jonah K. Stephan,Shizuka Uchida, Richa Singhal,Aisha Khan,Anna Gumpert,Roberto Bolli,Marcin Wysoczynski
STEM CELL REVIEWS AND REPORTSno. 7 (2023): 2429-2446
引用0浏览0引用
0
0
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2023)
引用0浏览0引用
0
0
Xian-Liang Tang, Marjan Nasr,Shirong Zheng,Taylor Zoubul,Jonah K Stephan,Shizuka Uchida, Richa Singhal,Aisha Khan,Anna Gumpert,Roberto Bolli,Marcin Wysoczynski
Stem cell reviews and reports (2023)
引用0浏览0WOS引用
0
0
JOURNAL OF TRANSLATIONAL MEDICINEno. 1 (2023)
Arteriosclerosis, Thrombosis, and Vascular Biologyno. Suppl_1 (2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn